Fig. 4: nferX single-cell platform analysis of NR3C1 expression.

In a study of peripheral blood samples from healthy donors (n = 6) and COVID-19 patients between days 2 and 16 of symptom onset (n = 7), NR3C1 was appreciably expressed in diverse immune cell types including T cells, B cells, dendritic cells, monocytes, and plasmacytoid dendritic cells.